Drug intelligence / Profile preview

BMS-986498

Development stage: Unknown
Lead developer: NewCo

Overview

BMS-986498 is a biologic drug candidate developed for autoimmune diseases. It is classified as a phase 1-ready biologic targeting the IL10 pathway, suggesting a mechanism involving modulation or agonism of interleukin-10 (IL-10), a cytokine with anti-inflammatory properties. The drug was initially developed by Bristol Myers Squibb and is being transferred to a new, yet unnamed, independent biotechnology company launched in partnership with Bain Capital. The focus for BMS-986498 is likely in diseases where alteration of immune tolerance or inflammation is beneficial, typical of autoimmune indications[7][9].

Beyond the preview

Go deeper on BMS-986498.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-986498.

Explore the full profile